English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/109288
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Cefditoren and ceftriaxone enhance complement-mediated immunity in the presence of specific antibodies against antibiotic-resistant pneumococcal strains

AuthorsRamos-Sevillano, Elisa CSIC; Rodríguez-Sosa, Cinthya; Cafini, Fabio; Giménez, María José; Navarro, Ana; Sevillano, David; Alou, Luis; García, Ernesto CSIC ORCID ; Aguilar, Lorenzo; Yuste, José CSIC ORCID
Issue Date5-Sep-2012
PublisherPublic Library of Science
CitationPLoS ONE 7(9): e44135
AbstractBackground: Specific antibodies mediate humoral and cellular protection against invading pathogens such as Streptococcus pneumoniae by activating complement mediated immunity, promoting phagocytosis and stimulating bacterial clearance. The emergence of pneumococcal strains with high levels of antibiotic resistance is of great concern worldwide and a serious threat for public health. Methodology/Principal Findings: Flow cytometry was used to determine whether complement-mediated immunity against three antibiotic-resistant S. pneumoniae clinical isolates is enhanced in the presence of sub-inhibitory concentrations of cefditoren and ceftriaxone. The binding of acute phase proteins such as C-reactive protein and serum amyloid P component, and of complement component C1q, to pneumococci was enhanced in the presence of serum plus either of these antibiotics. Both antibiotics therefore trigger the activation of the classical complement pathway against S. pneumoniae. C3b deposition was also increased in the presence of specific anti-pneumococcal antibodies and sub-inhibitory concentrations of cefditoren and ceftriaxone confirming that the presence of these antibiotics enhances complementmediated immunity to S. pneumoniae. Conclusions/Significance: Using cefditoren and ceftriaxone to promote the binding of acute phase proteins and C1q to pneumococci, and to increase C3b deposition, when anti-pneumococcal antibodies are present, might help reduce the impact of antibiotic resistance in S. pneumoniae infections.
Description8 p.-4 fig.
Publisher version (URL)http://dx.doi.org/10.1371/journal.pone.0044135
Appears in Collections:(CIB) Artículos
Files in This Item:
File Description SizeFormat 
PLOS_ONE 2012.Ernesto García.pdf897,77 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.